Kernicterus (Neonatal Jaundice) - Causes, Treatment & When to See a Doctor

What is Kernicterus (Neonatal Jaundice)?

Kernicterus, also called bilirubin‑induced neurologic dysfunction (BIND), is a rare but serious complication of severe neonatal jaundice. In newborns, high levels of unconjugated bilirubin—a yellow pigment produced when red blood cells break down—can cross the immature blood‑brain barrier and deposit in the basal ganglia and other brain structures. The resulting brain injury can cause permanent movement disorders, hearing loss, and developmental delays. While the term “neonatal jaundice” refers to any yellowing of the skin or eyes in a newborn, kernicterus specifically denotes the neurotoxic effects of extremely elevated bilirubin levels.

Most cases of neonatal jaundice are harmless and resolve with simple treatment (e.g., phototherapy). However, when bilirubin levels rise rapidly or remain high for several days, the risk of kernicterus increases. Early recognition, prompt treatment, and diligent follow‑up are essential to prevent this preventable cause of childhood disability.

Common Causes

About 60 % of newborns develop some degree of jaundice in the first week of life. Several physiological and pathological processes can push bilirubin into the toxic range.

• Physiologic jaundice – normal breakdown of fetal red blood cells; peaks 3–5 days after birth.
• Breast‑feeding jaundice – inadequate intake leading to dehydration and decreased bilirubin excretion.
• Breast‑feeding milk jaundice – substances in breast milk that inhibit bilirubin conjugation (often resolves after 2–3 weeks).
• Hemolytic disease of the newborn (HDN) – caused by ABO or Rh incompatibility, leading to rapid red‑cell destruction.
• G6PD deficiency – an inherited enzyme defect that makes red cells more fragile.
• Hereditary spherocytosis or other red‑cell membrane disorders – increase hemolysis.
• Crigler‑Najjar syndrome (type I) – rare genetic defect in the enzyme bilirubin‑UGT1A1, producing extremely high unconjugated bilirubin.
• Sepsis or severe infection – can impair liver function and increase hemolysis.
• Prematurity – immature liver enzymes and a more permeable blood‑brain barrier.
• Other metabolic disorders – e.g., hypothyroidism, which slows bilirubin metabolism.

Associated Symptoms

Early jaundice is usually identified by yellow discoloration of the skin and sclerae. As bilirubin levels climb, infants may show additional signs that suggest the bilirubin is affecting the central nervous system.

• Lethargy or difficulty waking for feeds
• Poor feeding or vomiting
• High‑pitched crying that is difficult to soothe
• Hypotonia (floppy‑baby appearance) or, conversely, hypertonia and spasticity
• Arching of the back (opisthotonus)
• Seizures (especially subtle, focal seizures)
• Midline “cough” or “grimace” during handling (reflecting brainstem involvement)
• Auditory deficits – infants may not startle to loud noises
• Later‑onset motor abnormalities such as choreoathetoid movements (involuntary writhing)

When to See a Doctor

All newborns should have a bilirubin check before discharge and during the first week of life, but parents should call a pediatrician or go to an urgent care center immediately if any of the following occur:

• Yellowing that spreads to the chest, abdomen, or limbs
• Yellowing of the whites of the eyes (scleral icterus)
• Baby is unusually sleepy, difficult to wake, or refuses to feed
• Vomiting, especially after feeds
• High‑pitched or inconsolable crying
• Any seizure‑like activity or abnormal eye movements
• Rapid weight loss (>10 % of birth weight) suggesting dehydration

Prompt evaluation can prevent bilirubin from reaching neurotoxic levels.

Diagnosis

Diagnosis combines a clinical assessment with quantitative measurements.

1. Physical Examination

Clinicians assess the distribution and intensity of jaundice using the “Kramer rule” (skin blanching on the torso) and check for neurologic signs (tone, reflexes, responsiveness).

2. Serum Bilirubin Levels

• Total serum bilirubin (TSB) – the primary lab value; >25 mg/dL (≈425 µmol/L) in term infants is often the threshold for aggressive treatment.
• Direct (conjugated) vs. indirect (unconjugated) bilirubin – Kernicterus results from very high unconjugated bilirubin.

3. Transcutaneous Bilirubinometer

Non‑invasive devices (e.g., BiliChek) give rapid readings that correlate well with serum levels, useful for screening.

4. Blood Type and Coombs Test

Identify hemolytic disease caused by ABO or Rh incompatibility.

5. Additional Labs (if indicated)

• Complete blood count (CBC) – looks for anemia or hemolysis.
• Reticulocyte count – elevated in hemolytic processes.
• G6PD assay – especially in populations with higher prevalence.
• Liver function tests – rule out cholestasis or hepatic dysfunction.

6. Neuroimaging (rare, for severe cases)

If kernicterus is suspected despite treatment, MRI may show hyperintensity in the basal ganglia.

Treatment Options

The goal of therapy is to lower serum bilirubin quickly enough to keep it below neurotoxic thresholds while avoiding complications of treatment.

Phototherapy

Broad‑band or LED blue‑light converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation. Key points:

• Standard intensive phototherapy starts at ~30 cm distance, 12–24 hr/day.
• Double‑surface (both infant’s back and front) phototherapy is more effective.
• Monitor bilirubin every 4–6 hours; continue until levels fall below the treatment line on the nomogram.

Exchange Transfusion

Reserved for bilirubin levels that exceed the exchange threshold (≈20–25 mg/dL in term infants) or when phototherapy fails. Blood is removed and replaced with donor blood, rapidly decreasing bilirubin and reducing the risk of ongoing hemolysis.

Intravenous Immunoglobulin (IVIG)

Used in hemolytic disease of the newborn (HDN) due to maternal antibodies. A single dose (1 g/kg) can reduce the need for exchange transfusion.

Supportive Measures

• Ensure adequate feeding – frequent breastfeeding or formula feeds to promote stool output and bilirubin excretion.
• Hydration – especially important in preterm infants.
• Correct underlying causes (e.g., treat infection, stop drugs that impair bilirubin metabolism).

Long‑Term Management for Affected Infants

Infants who develop kernicterus need multidisciplinary follow‑up:

• Neurology – monitor for movement disorders, cerebral palsy.
• Audiology – early hearing screening and ongoing assessments.
• Developmental pediatrics – early intervention services for speech, occupational, and physical therapy.
• Ophthalmology – assess for visual deficits.

Prevention Tips

Because kernicterus is almost always preventable, the following strategies are recommended for all newborns, especially those at higher risk (prematurity, hemolytic disease, family history).

• Early bilirubin screening – check levels before hospital discharge and at 24‑48 hr for high‑risk babies.
• Encourage frequent feeding – aim for at least 8–12 breastfeeds or formula feeds per 24 hr to promote stooling.
• Monitor weight loss – infants should lose <10 % of birth weight in the first 24 hr; greater loss suggests inadequate intake.
• Educate parents – teach how to recognize yellowing of the skin and eyes, and when to seek care.
• Use of prophylactic phototherapy – in some high‑risk preterm infants (≤35 weeks gestation), early phototherapy reduces severe jaundice rates.
• Avoid unnecessary medications – certain drugs (e.g., sulfonamides, some antibiotics) can displace bilirubin from albumin.
• Blood type screening of mother and baby – identify ABO/Rh incompatibility early.
• Genetic counseling – for families with known enzyme deficiencies (G6PD, Crigler‑Najjar).

Emergency Warning Signs

If any of the following appear, seek emergency medical care (call 911 or go to the nearest emergency department) immediately:

• Rapidly increasing yellow coloration, especially spreading to the torso and limbs
• Severe lethargy or inability to wake for feedings
• High‑pitched, continuous crying that cannot be soothed
• Vomiting or poor feeding persisting >2 hours
• Seizure‑like activity (stiffening, rhythmic jerking, eye deviation)
• Temperature >38 °C (100.4 °F) or <35 °C (95 °F) – possible infection compounding jaundice
• Signs of dehydration: sunken fontanelle, dry mucous membranes, >10 % weight loss

Early intervention can save the newborn’s brain and prevent lifelong disability. If you are ever uncertain about your baby’s jaundice, it is safer to have a clinician evaluate the infant.

References: Mayo Clinic. “Neonatal jaundice”; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia, 2022 Guidelines; CDC. “Neonatal Jaundice”; National Institute of Child Health and Human Development; WHO. “Management of Hyperbilirubinemia in the Newborn”; Cleveland Clinic. “Kernicterus”.